Key result
Tumor vascular endothelial cells contribute to cancer therapy resistance by secreting immune-modulating angiocrine factors.
Why the study?
Understanding complex endothelial cell-immune interactions within the tumor microenvironment is crucial for developing strategies to target the angiocrine axis and improve patient outcomes.
Design
Review
Authors
Loading...
May alter approaches to therapeutic resistance in solid tumors; extends endothelial-immune interface as actionable target for novel therapies.
Understanding the complex interactions between vascular endothelial cells and the immune system in the tumor microenvironment is crucial for developing novel strategies to overcome cancer therapy resistance.
Lockwood et al. (2026) conducted a review in Cancer. Vascular endothelial cells (angiocrine niche) was evaluated. Vascular endothelial cells within the tumor microenvironment act as immune gatekeepers, secreting angiocrine factors that modulate the immune landscape and contribute to cancer therapy resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: